Cornerstone Pharmaceuticals, Inc. Announces Corporate Name Change to Rafael Pharmaceuticals, Inc.
June 05, 2017 11:00 ET
|
Cornerstone Pharmaceuticals
Newark, NJ, June 05, 2017 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical-stage, oncology-focused pharmaceutical company, today announced that it is changing its corporate name to...
Cornerstone Pharmaceuticals to Present at the BioNJ 7th Annual BioPartnering Conference, May 23, 2017
May 22, 2017 14:00 ET
|
Cornerstone Pharmaceuticals
Cranbury, NJ, May 22, 2017 (GLOBE NEWSWIRE) -- Information on Cornerstone's upcoming presentation at this prestigious industry conference provided below: WHAT: In partnership with J.P....
The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
May 09, 2017 11:15 ET
|
Cornerstone Pharmaceuticals
Cranbury, NJ, May 09, 2017 (GLOBE NEWSWIRE) -- Cranbury, N.J., May 09, 2017 --(GlobeNewswire)-- Cornerstone Pharmaceuticals, Inc., a clinical-stage, oncology-focused pharmaceutical company, today...
Cornerstone Pharmaceuticals Receives Funding Through New Jersey's Technology Business Tax Certificate Transfer Program
January 21, 2015 13:22 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the field of cancer metabolism-based therapeutics, today announced that it...
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Metastatic Colorectal Cancer
January 12, 2015 10:38 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the field of cancer metabolism-based therapeutics, today announced the...
Cornerstone Pharmaceuticals Commences Phase I Clinical Trial of CPI-613 for the Treatment of B-Cell Non-Hodgkin Lymphoma
December 05, 2014 08:30 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 5, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced...
Cornerstone Pharmaceuticals' CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting Oncology Projects to Watch
November 13, 2014 12:28 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today...
Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be Presented at 2014 ASH Annual Meeting
November 06, 2014 09:52 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced...
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin's or T-Cell Non-Hodgkin's Lymphoma
October 21, 2014 12:13 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced...
Cornerstone Pharmaceuticals Appoints Steve Carchedi Chief Executive Officer
October 09, 2014 13:33 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced...